<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ideaya Biosciences Inc — News on 6ix</title>
    <link>https://6ix.com/company/ideaya-biosciences-inc</link>
    <description>Latest news and press releases for Ideaya Biosciences Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ideaya-biosciences-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683581f578dffbe2df0fc103.webp</url>
      <title>Ideaya Biosciences Inc</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc</link>
    </image>
    <item>
      <title>IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-metastatic-uveal-melanoma-6</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-metastatic-uveal-melanoma-6</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today</description>
    </item>
    <item>
      <title>IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-and-servier-announce-positive-topline-results-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-first-line-hla-a0201-negative-metastatic-uveal-melanoma</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-and-servier-announce-positive-topline-results-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-first-line-hla-a0201-negative-metastatic-uveal-melanoma</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus</description>
    </item>
    <item>
      <title>IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-to-announce-topline-results-from-phase-23-optimum-02-trial-in-metastatic-uveal-melanoma-on-monday-april-13-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-to-announce-topline-results-from-phase-23-optimum-02-trial-in-metastatic-uveal-melanoma-on-monday-april-13-2026</guid>
      <pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide574-a-potential-first-in-class-dual-inhibitor-of-kat67-to-target-multiple-solid-tumor-indications-including-breast-prostate-crc-and-lung-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide574-a-potential-first-in-class-dual-inhibitor-of-kat67-to-target-multiple-solid-tumor-indications-including-breast-prostate-crc-and-lung-cancer</guid>
      <pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
      <description>Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-combination-study-of-ide849-dll3-top1-adc-and-ide161-parg-inhibitor-in-dll3-upregulated-solid-tumor-indications-including-sclc-nets-necs-and-melanoma</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-combination-study-of-ide849-dll3-top1-adc-and-ide161-parg-inhibitor-in-dll3-upregulated-solid-tumor-indications-including-sclc-nets-necs-and-melanoma</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-upcoming-investor-relations-events-and-updated-darovasertib-topline-results-guidance-from-phase-23-optimum-02-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-upcoming-investor-relations-events-and-updated-darovasertib-topline-results-guidance-from-phase-23-optimum-02-trial</guid>
      <pubDate>Sun, 22 Mar 2026 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-upcoming-presentations-at-aacr-2026-highlighting-multiple-clinical-stage-pipeline-programs</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-upcoming-presentations-at-aacr-2026-highlighting-multiple-clinical-stage-pipeline-programs</guid>
      <pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide892-a-potential-best-in-class-prmt5-inhibitor-for-mtap-deleted-solid-tumors-and-provides-mtap-and-cdkn2a-pipeline-update</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide892-a-potential-best-in-class-prmt5-inhibitor-for-mtap-deleted-solid-tumors-and-provides-mtap-and-cdkn2a-pipeline-update</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide034-a-potential-first-in-class-b7h3ptk7-bispecific-top1-adc</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide034-a-potential-first-in-class-b7h3ptk7-bispecific-top1-adc</guid>
      <pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
      <description>Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034Potential as a monotherapy and in combination with proprietary PARG inhibitor,</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-appointment-of-dr-theodora-theo-ross-md-phd-as-chief-development-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-appointment-of-dr-theodora-theo-ross-md-phd-as-chief-development-officer</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</guid>
      <pubDate>Tue, 17 Feb 2026 11:00:00 GMT</pubDate>
      <description>IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2025.</description>
    </item>
    <item>
      <title>IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-participate-upcoming-february-2026-investor-relations-events-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-participate-upcoming-february-2026-investor-relations-events-2026</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 2, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</guid>
      <pubDate>Fri, 30 Jan 2026 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-provides-business-update-and-outlines-2026-corporate-objectives</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-provides-business-update-and-outlines-2026-corporate-objectives</guid>
      <pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-participation-44th-annual-jp-morgan-healthcare</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-participation-44th-annual-jp-morgan-healthcare</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-completes-targeted-full-enrollment-randomized-pivotal-phase-2-3</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-completes-targeted-full-enrollment-randomized-pivotal-phase-2-3</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trialTopline data, including median PFS, are</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-ind-submission-ide574-potential-first-class-kat6-7-dual</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-ind-submission-ide574-potential-first-class-kat6-7-dual</guid>
      <pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
      <description>Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026Targeting to present preclinical data detailing pharmacologic profile and</description>
    </item>
    <item>
      <title>IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ide034-a-bispecific-adc-licensed-by-biocytogen-to-ideaya-receives-fda-ind-clearance</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ide034-a-bispecific-adc-licensed-by-biocytogen-to-ideaya-receives-fda-ind-clearance</guid>
      <pubDate>Fri, 05 Dec 2025 00:00:00 GMT</pubDate>
      <description>BEIJING, December 05, 2025--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enroll</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-ind-clearance-ide034-potential-first-class-bispecific</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-announces-ind-clearance-ide034-potential-first-class-bispecific</guid>
      <pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
      <description>B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%,</description>
    </item>
    <item>
      <title>IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events</title>
      <link>https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-participate-upcoming-december-2025-investor-relations-events-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ideaya-biosciences-inc/news/ideaya-biosciences-participate-upcoming-december-2025-investor-relations-events-2025</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the</description>
    </item>
  </channel>
</rss>